CGTX

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Purchase, New York, dedicated to pioneering small molecule therapies for age-related neurodegenerative diseases and retinal disorders. With a robust focus on enhancing cognitive health and vision in the aging population, the company is actively advancing its innovative pipeline through cutting-edge research and development initiatives. Cognition Therapeutics's proprietary drug design capabilities position it to offer transformative treatment options, addressing the growing demand for effective therapies in the rapidly expanding fields of neurodegeneration and age-related vision impairment.